Drug Trial Radar · NCT02640482
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Last checked: Nov 20, 2026Latest source record: Jul 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
Nov 2015
Primary completion
Sep 2016
Study completion Feb 2017
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
Conditions
- Chronic Hepatitis C Virus (HCV) Infection
Interventions
ABT-493/ABT-530Drug
Tablet; ABT-493 coformulated with ABT-530
Placebo for ABT-493/ABT-530Drug
tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures: Noninferiority AnalysisTime frame: 12 weeks after the last actual dose of active study drug
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.